Literature DB >> 2455520

Effects of methotrexate on purine and pyrimidine metabolism and cell-kinetic parameters in human malignant lymphoblasts of different lineages.

J P Bökkerink1, R A De Abreu, M A Bakker, T W Hulscher, J M van Baal, E D Schretlen, C H De Bruijn.   

Abstract

MOLT-4 (T-), RAJI (B-), and KM-3 (non-B-non-T-, common ALL) malignant lymphoblasts demonstrated significant differences in their activities of purine de novo synthesis (PDNS) and purine salvage pathway and in their cell-kinetic parameters. Incubations with concentrations of methotrexate (0.02 and 0.2 microM), which can be maintained during many hours in the oral maintenance therapy of acute lymphoblastic leukemia, indicated large differences between the three cell lines with respect to the inhibition of PDNS, depending on the concentration of methotrexate (MTX) and on the activities of the two pathways. These dose- and cell line-dependent differences corresponded to the perturbations of cell-kinetics and purine and pyrimidine (deoxy)ribonucleotide pools in the three cell lines. Exposure of MOLT-4 cells to 0.02 microM MTX resulted in an incomplete inhibition of DNA synthesis in early S phase, as shown by DNA-flow cytometry and increase of dCTP levels, which recovered spontaneously after 48 hr. Almost no impairment of RNA synthesis occurred (unbalanced growth). In RAJI cells, exposed to 0.02 microM MTX, DNA synthesis was delayed in the S phase, not arrested, and RNA synthesis was not impaired, also indicating an unbalanced growth pattern, which, however, did not recover in time. KM-3 cells were arrested in G1 phase and subsequently in early S phase after incubation with 0.02 microM MTX, and perturbations of ribonucleotides indicated a complete inhibition of RNA synthesis, resulting in a balanced growth pattern. Cytotoxicity was more pronounced in KM-3 cells. The reliability of the soft agar colony forming assay after low dose MTX treatment is discussed. Exposure of MOLT-4 and KM-3 cells to 0.2 microM MTX resulted in a complete inhibition of DNA synthesis, with cessation of cell progression through all parts of the cell cycle and arrest in G1 phase. RAJI cells showed an increasing accumulation of cells in G1 phase without complete cessation of cell cycle progression. Perturbations of ribonucleotide pools suggested an inhibition of RNA synthesis in all cell lines, indicating a balanced growth pattern in KM-3 cells and MOLT-4 cells.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2455520     DOI: 10.1016/0006-2952(88)90359-0

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

1.  Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial.

Authors:  Torben S Mikkelsen; Alex Sparreboom; Cheng Cheng; Yinmei Zhou; James M Boyett; Susana C Raimondi; John C Panetta; W Paul Bowman; John T Sandlund; Ching-Hon Pui; Mary V Relling; William E Evans
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

2.  Methotrexate cytotoxicity as related to irreversible S phase arrest in mouse L1210 leukemia cells.

Authors:  M Tsurusawa; M Niwa; N Katano; T Fujimoto
Journal:  Jpn J Cancer Res       Date:  1990-01

3.  Immune Response-Dependent Assembly of IMP Dehydrogenase Filaments.

Authors:  S John Calise; Georges Abboud; Hideko Kasahara; Laurence Morel; Edward K L Chan
Journal:  Front Immunol       Date:  2018-11-29       Impact factor: 7.561

4.  Mechanism of Action of Methotrexate Against Zika Virus.

Authors:  Sungjun Beck; Zhe Zhu; Michelli F Oliveira; Davey M Smith; Jeremy N Rich; Jean A Bernatchez; Jair L Siqueira-Neto
Journal:  Viruses       Date:  2019-04-10       Impact factor: 5.048

5.  Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours.

Authors:  Corran Roberts; Victoria Y Strauss; Sylwia Kopijasz; Charlie Gourley; Marcia Hall; Ana Montes; Jacinta Abraham; Andrew Clamp; Richard Kennedy; Susana Banerjee; Lisa K Folkes; Michael Stratford; Shibani Nicum
Journal:  Br J Cancer       Date:  2019-12-09       Impact factor: 7.640

Review 6.  Biomarkers Predictive of Response to Thiopurine Therapy in Inflammatory Bowel Disease.

Authors:  Jack S Cornish; Elisa Wirthgen; Jan Däbritz
Journal:  Front Med (Lausanne)       Date:  2020-01-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.